CCO Oncology Podcast

Expert Insight on Key Data From SGO 2021 Informing Treatment for Endometrial and Ovarian Cancer

Episode Summary

In this podcast episode, listen to Ursula Matulonis, MD, and Jubilee Brown, MD, discuss new data for gynecological cancers presented at the virtual SGO 2021 meeting, including immunotherapy-based combinations for endometrial cancer and PARP inhibitors for BRCA-mutated ovarian cancers.

Episode Notes

In this episode, Jubilee Brown, MD, and Ursula Matulonis, MD, provide expert perspectives on new data from SGO 2021 presented for endometrial and ovarian cancer including:

• Results from KEYNOTE-775, a phase III trial of lenvatinib plus pembrolizumab in advanced endometrial cancer
• Results from the confirmatory phase III ARIEL4 evaluating rucaparib vs chemotherapy in BRCA-mutated relapsed ovarian cancer
• 5-year follow-up from SOLO-1 trial of olaparib vs placebo in BRCA-mutated, newly diagnosed ovarian cancer
• Long-term follow-up results from the phase III ENGOT-OV16/NOVA trial of niraparib in patients with recurrent ovarian cancer
• OPAL: a phase II study evaluating dostarlimab, bevacizumab, and niraparib in platinum-resistant ovarian cancer

Presenters:

Jubilee Brown, MD
Professor and Director of Gynecologic Oncology
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina

Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Content supported by an educational grant from GlaxoSmithKline.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/3dAttwi